Adelaide Research
& Innovation

advanced

	Technology Portfolio

	Register Your Interest

Further Enquiries:
Adelaide Research & Innovation
Level 7, 115 Grenfell St
Adelaide SA 5000

Mailing Address:
PO Box 149
Rundle Mall
Adelaide SA 5000

Ph: +61 8 8303 5020
Fax: +61 8 8303 4355
Email: aripl@adelaide.edu.au

ACN 008 027 085

ARIPL Home > Technology Portfolio

Print View

Technology Portfolio

The University’s IP portfolio comprises patents and patent applications as well as a number of non-patented technologies, software developments and trademarks. ARI is seeking commercial interest for a number of innovative technologies that have commercial application, particularly in the following areas:

New!

Bragg Crystallography Facility
From 2010, this Facility will be equipped with 2 diffractometers for small and large molecule structure determination. This technology can determine the exact 3D arrangement of atoms in a structure, including the relative positions, bonding and interactions.

Biomedical

	ES Cell Isolation A method to efficiently isolate embryonic stem (ES) cells from preimplantation mammalian embryos.
	MRI-based analysis of blood flow Software that interpolates images obtained preferably from magnetic resonance imaging (MRI) techniques to analyse blood flow characteristics of the cardiac pathology, particularly the heart and arteries.
	Biotin Protein Ligase A target for the development of anti-bacterials, anti-fungals and even herbicides. We have also produced a novel technology for screening for inhibitors of this enzyme.
	Treatment for Ischaemic Stroke This invention significantly improves outcomes associated with ischaemic stroke and its current therapies, including the reduction of cerebal oedema.
	Melanoma Vaccine A novel treatment for stage IV (late stage) melanoma that has been shown to reduce melanoma in approx 20% of patients tested and slow down the rate of cancer progression in more than 80% of patients treated. In phase II clincal trial.
	Novel Cancer Therapeutic: IGF Binding Protein 2 Novel variants of the human Insulin-like Growth Factor (IGF) Binding Protein 2 have been developed that are able to sequested IGF's and prevent the growth of cancer cells that are dependent on IGF's.
	Vaccination for STEC Cytotoxin It is likely that a new AB5 toxin class is responsible for disease in humans and in animals. If this proves to be the case, then the current work will provide the basis for effective diagnostic, therapeutic and vaccination strategies.
	Monoclonal Antibody to the IGF Receptor The IGF growth factors and their receptor play an important role in growth and proliferation of cancer cells. We have developed a mouse monoclonal antibody to the human IGF receptor.
	Asparagine Hydroxylation of Human HIF HIF (hypoxia-inducible factor) proteins are transcription factors that are regulators in the detection and response to levels of oxygenation in tissues. We have characterised the site of this modication in human HIF, and a screening method has been developed.

Reproductive Health

	Screening for Obstetrics & Pregnancy End Points Program (SCOPE) The University of Adelaide are part of the international SCOPE program, which aims to recruit 15,000 patients globally, taking samples from mother, baby and father to build a pregnancy biobank to screen candidate markers of pregnancy disease.
	Novel Target for Drugs that Manipulate Ovulation Involves exploiting the BMPRII receptor, responsible for the transmission of all oocyte-paracine growth factors to follicular granulosa cells, which in turn regulates folliculogenesis and ovuation for the purpose of fertility management or maintenance of ovarian reserve for women who delay childbirth.
	Treatment and Diagnosis of an Infertility Condition The invention relates to estimating levels of interferon-y in diagnosis of a fertility condition, use of an y inhibitor in inducing GM-CSF synthesis and a tolerance reaction to exogenous antigens at mucosal surfaces, for enhancing a positive fertility outcome.

Agriculture, Food & Wine

New Applications for Barley
We have discovered two separate environmentally friendly agents, one based on a bacteriological product and a second based on polymer technology, which significantly assist plant uptake of trace elements. Our products are less expensive and more effective than those synthetic chelating agents currently used in fertilisers to promote uptake into plants in micronutrient deficient areas.

Chelating agents for fertilisers
We have discovered two separate environmentally friendly agents, one based on a bacteriological product and a second based on polymer technology, which significantly assist plant uptake of trace elements. Our products are less expensive and more effective than those synthetic chelating agents currently used in fertilisers to promote uptake into plants in micronutrient deficient areas.

Engineering, Computer & Maths

	Optical Testing: A differential Hartmann Sensor with higher accuracy and precision with applications in ophthalmology, advanced optics, optometry, lens manufacturing, refractive optical tomography and laser beam characterisation.
	BioVision: Adelaide Insect Vision Group The Vision Group's research investigates how the brain makes sense of the world viewed by the eye.
	Coherent Laser Radar Developing an eye-safe laser radar, or lidar, for coherent remote sensing of atmospheric wind fields. This system will be able to predict and monitor dispersion of pollutants in the planetary boundary layer, and detect clear-air turbulence and wind-shear in front of aircraft.

Other

Hair Removal Technology
This discovery is an enzyme mixture for the removal of unwanted body hair. Rights for the use of this technology for sheep in Australia have already been granted, but there are further possible veterinary and human applications.

Disclaimer: Information about the portfolio has been prepared on a best endeavours basis but neither ARI Pty Ltd nor the University of Adelaide warrant that the information is accurate or complete. If you are interested in any of the technologies please contact us to discuss. Naturally you will need to undertake your own due diligence and make your own assessment about the prospects of any opportunity. Information on this site does not constitute nor is it intended to constitute the provision of financial product advice.